Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022)
Roivant Sciences' (ROIV) quarterly Non-Current Deffered Revenue came in at $11.9 million in Q3 2022, down 9.47% quarter-over-quarter from $13.1 million in Q2 2022.
Powered by 
Analysis
Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022) Analysis & Trends
Roivant Sciences (ROIV) has reported Non-Current Deffered Revenue for 1 consecutive years, with $11.9 million the latest figure, recorded in Q3 2022.
- For the quarter ending Q3 2022, Non-Current Deffered Revenue changed N/A year-over-year to $11.9 million; the trailing twelve-month figure through Sep 2022 stood at $11.9 million (changed N/A YoY), and the FY2022 full-year result was $13.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue eased to $11.9 million in Q3 2022 per ROIV's latest filing, from $13.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $13.7 million in Q1 2022 and bottomed at $11.9 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.32 Bn | 27.16 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 11.90 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 13.74 Mn |